All section Close
Credits: Firstpost
COVID-19: Indian Drugmaker Biological E Signs Deal With J&J, Houston College For Vaccine Production
Writer: Devyani Madaik
A media enthusiast, Devyani believes in learning on the job and there is nothing off limits when it comes to work. Writing is her passion and she is always ready for a debate as well.
India, 16 Aug 2020 10:20 AM GMT
Editor : Shubhendu Deshmukh |
Shubhendu, the quint essential news junky, the man who loves science and politics in equal measure and offers the complete contrast to it by being a fan of urdu poetry as well.
Creatives : Abhishek M
" An engineer by profession, Abhishek is the creative producer of the team, graphic designing is his passion and travelling his get away. In more ways than one, he makes the content visually appealing."
It is the second pharmaceutical company in India to announce the agreements on developing the vaccines after Pune-based Serum Institute Of India that entered into similar agreements with AstraZeneca, which is developing a vaccine with Oxford University.
Hyderabad-based Biological E has signed two agreements for the development of novel Coronavirus vaccines, one with Janssen Pharmaceutica NV, which is a part of drug giant Johnson & Johnson, and with Houston-based Baylor College of Medicine.
It is the second pharmaceutical company in India to announce the agreements on developing the vaccines after Pune-based Serum Institute Of India that entered into similar agreements with AstraZeneca, which is developing a vaccine with Oxford University.
As a part of the deal, J&J will be transferring technology for manufacturing its vaccine. Biological E will begin production of the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate that is in early to mid-stage trials, Reuters reported.
The drug giant aims to develop more than a billion doses of its vaccine candidate ' Ad26.COV2-S'. Currently, it is in combined Phase 1 and 2 of human trials and expects to enter Phase 3 by the month of September in view of making the vaccine available by next year.
In the second agreement the Hyd- based company has licensed the vaccine produced by the college, which is presently in its pre-clinical trials. According to the agreement, Biological E will manufacture the vaccine, and will collaborate on its further development, The Indian Express reported.
"The production of the vaccine at Biological E could facilitate its deployment in India and other middle and low-income countries," the company's statement as quoted.
Other Indian companies developing or manufacturing potential COVID-19 vaccines include the Serum Institute, Wockhardt Ltd, Cadila Healthcare Ltd and Panacea Biotec Ltd.
On Thursday, India reported a record daily jump of 67,000 coronavirus infections, taking its total to nearly 2.4 million, having the third-largest number of cases after the United States and Brazil.
Also Read: Former Congress Corporator Among 60 More Arrested In Bengaluru Riots Connection
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
